Juan Manuel Sepúlveda-Sánchez

Author

Hospital Universitario 12 De Octubre ORCID

Also Known As

Anna Neyman, Guillermo Blasco, J M Sepulveda, J M Sepulveda Sanchez, J M Sepúlveda, J M Sepúlveda-Sánchez, J Sanchez, J Sepulveda, J Sepúlveda, J. M. Sepulveda

444

Publications

7.7K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario 12 De Octubre Research Institute Hospital 12 de Octubre Erasmus MC Cancer Institute Instituto de Salud Carlos III Istituti di Ricovero e Cura a Carattere Scientifico

About

Juan Manuel Sepúlveda-Sánchez is an author at Hospital Universitario 12 De Octubre specializing in medicine, neuro-oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	27	868
2	Health Sciences	7	7	113
3	Engineering	2	2	55
4	Cell Biology	2	2	207
5	Molecular Medicine	1	1	40

Juan Manuel Sepúlveda-Sánchez

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma David A. Reardon, Alba A. Brandes, Antonio Omuro, JAMA Oncology	2020	1.4K
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal, New England Journal of Medicine	2023	606
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial Antonio Omuro, Alba A. Brandes, Ahmed Idbaïh, Neuro-Oncology	2022	435
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma Alba A. Brandes, Santosh Kesari, Juan Manuel Sepúlveda-Sánchez, Neuro-Oncology	2016	264
First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma Jordi Rodón, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez, Clinical Cancer Research	2014	229
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma Martin J. van den Bent, Marica Eoli, Juan Manuel Sepúlveda-Sánchez, Neuro-Oncology	2019	180
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth Natividad Pozo, Cristina Zahonero, Paloma Fernández, Journal of Clinical Investigation Neuro-oncologyGbm Tumor-initiating CellsGliomaMedicineReceptor Tyrosine Kinase	2013	135
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, JAMA Oncology	2022	129
Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification Juan Manuel Sepúlveda-Sánchez, María Ángeles Vaz Salgado, Carmen Balañá, Neuro-Oncology	2017	119
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study Richard J. Kovacs, Giuliana Maldonado, Analía Azaro, Cardiovascular Toxicology Tgf-β ReceptorCardiovascular PharmacologyPathologyPharmacotherapyCancer Patients	2014	109

Page 1